2021
Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.
Afghahi A, Marsh S, Winchester A, Gao D, Parris H, Axell L, Ellisen L, Hofstatter E, Kurian A, Wood M, Zakalik D, Mullin C, Caswell-Jin J, Borges V, Tung N. Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study. Journal Of Clinical Oncology 2021, 39: 10531-10531. DOI: 10.1200/jco.2021.39.15_suppl.10531.Peer-Reviewed Original ResearchCHEK2 pathogenic variantsRecurrence scoreCase-control studyMedian RSBreast cancerPathogenic variantsHigh riskRisk groupsMutation statusHER2-negative BC patientsPR-negative breast cancerMulti-site case-control studyPatient-level clinical dataRS risk groupsLymph node statusHigh recurrence scoreLow-risk groupGermline pathogenic variantsSporadic breast cancerGenetic testing resultsElectronic medical recordsAdjuvant therapyChemotherapy benefitNode statusT stage
2013
The impact of survivorship care plans on knowledge among breast cancer survivors.
Bulloch K, Irwin M, Chagpar A, Horowitz N, Killelea B, Pusztai L, Abu-Khalaf M, DiGiovanna M, Chung G, Hofstatter E, Levy A, Sanft T. The impact of survivorship care plans on knowledge among breast cancer survivors. Journal Of Clinical Oncology 2013, 31: 124-124. DOI: 10.1200/jco.2013.31.26_suppl.124.Peer-Reviewed Original ResearchSurvivorship care plansPotential side effectsSurveillance recommendationsSide effectsPatient knowledgeCancer survivorsCare plansLong-term side effectsCancer treatmentTreatment progressMedian patient ageBreast cancer survivorsCompletion of treatmentKnowledge of treatmentElectronic medical recordsOnly significant improvementPatient ageProspective studyTreatment detailsTumor stageCancer stageMedical recordsRisk factorsMedicine recommendationsStage IIIRothman index as a predictor for type of discharge and readmission rates in a cancer hospital: The Yale experience.
Morgensztern D, Xia B, Kournioti C, Hofstatter E, Raucci M, Keyes A, Morrione A, Blasiak E, Rosenberg E, Rimar J, Rothman M, Lilenbaum R. Rothman index as a predictor for type of discharge and readmission rates in a cancer hospital: The Yale experience. Journal Of Clinical Oncology 2013, 31: 6635-6635. DOI: 10.1200/jco.2013.31.15_suppl.6635.Peer-Reviewed Original ResearchTime of dischargeRothman IndexElectronic medical recordsCancer HospitalRA ratesEvaluation of inpatientsSmilow Cancer HospitalDC typesPredictors of dischargeRate of readmissionHospital electronic medical recordsLength of stayHealth care providersRI meanOncology inpatientsReadmission ratesMedian ageProspective studyNursing assessmentCommon tumorsElective admissionsMedical recordsDisposition planningCare providersReadmission